A Phase 1/2 interventional study of pemetrexed and cisplatin in Small Cell Lung Cancer, Carcinoma, Small Cell and SCLC, sponsored by Eli Lilly and Company. Terminated at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-10-28.
Sponsored by Eli Lilly and Company · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing cisplatin in Small Cell Lung Carcinoma — 2 open to participants now, 2 under way, none of them phase 3. Cisplatin · Small Cell Lung Carcinoma.
Among the 33 studies testing cisplatin in Small Cell Lung Carcinoma, this one is the 25th largest by enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2007, is one of 4 in phase 1/2, and was the 17th registered.
1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.
Browse Small Cell Lung Carcinoma studies →2 of the 33 studies testing cisplatin in Small Cell Lung Carcinoma are open now, in 1 country. Recruiting first, the newest first:
Anhui Provincial Cancer Hospital · Sites in China
Ages 18+
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Ages 18–70
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 19 · Phase 3 8
First in 1999; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 9 is below the median of 56 across 1,077 interventional studies indexed under Small Cell Lung Carcinoma.
Median enrollment 62 across the 32 interventional studies. Of the 26 that completed or were terminated, 6 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 33 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
12 studies in Small Cell Lung Carcinoma by Eli Lilly and Company: none open now, 1 under way, none of them phase 3. Of 11 finished, 9 (82%) have results posted.
Among the 12 studies in Small Cell Lung Carcinoma by Eli Lilly and Company, this one is the 10th largest by enrollment, is one of 3 that started in 2007, is one of 3 in phase 1/2, and was the 4th registered.
Eli Lilly and Company’s Small Cell Lung Carcinoma studies by the year they started, since 1998.
1 of the studies testing cisplatin in Small Cell Lung Carcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06838208Anhui Provincial Cancer HospitalTislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 33 studies testing cisplatin in Small Cell Lung Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 12 in Small Cell Lung Carcinoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the recommended dose of pemetrexed, cisplatin and radiotherapy in the treatment of patients with Small Cell Lung Cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: pemetrexed · Drug: cisplatin · Radiation: radiation
Phase 1: 500 mg/m2 then 400 mg/m2, intravenous (IV), every 21 days x 4 cycles (dose escalation) Phase 2: 500 mg/m2 then phase 1 determined dose, IV, every 21 days x 4 cycles
Also known as: LY231514, Alimta
Phase 1 and Phase 2: 75 mg/m2, intravenous (IV), every 21 days x 4 cycles
Phase 1 and Phase 2: 50-62 Gy, 25-31 days, cycles 2-4
Phase 1: Maximum Tolerated Dose
Time frame: every cycle
Phase 2: Overall Response Rate
Overall Response Rate (ORR) was defined as the proportion of participants having either a Complete or Partial response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions.
Time frame: baseline to measured progressive disease
Phase 1: Best Overall Response
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
Time frame: baseline to measured response
Phase 2: Complete Response Rate
Complete Response Rate was defined as the proportion of participants having a Complete Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions.
Time frame: baseline to measured response time
Phase 2: Time to Progressive Disease
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.
Time frame: baseline to measured progressive disease
Phase 2: Duration of Response
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
Time frame: time of response to progressive disease
Phase 2: Overall Survival
Overall survival was the duration from enrollment to death. For patients who were alive, overall survival was censored at the last contact.
Time frame: baseline to date of death from any cause
| Milestone | Pemetrexed + Cisplatin |
|---|---|
| Started | 9 |
| Completed | 3 |
| Not completed | 6 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Adverse event | 3 |
| Withdrew: Sponsor decision | 2 |
No measurements were reported for this outcome.
Overall Response Rate (ORR) was defined as the proportion of participants having either a Complete or Partial response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions.
No measurements were reported for this outcome.
Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria.
No measurements were reported for this outcome.
Complete Response Rate was defined as the proportion of participants having a Complete Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions.
No measurements were reported for this outcome.
Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause.
No measurements were reported for this outcome.
The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause.
No measurements were reported for this outcome.
Overall survival was the duration from enrollment to death. For patients who were alive, overall survival was censored at the last contact.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed + Cisplatin | — | — | — |
| Event | Pemetrexed + Cisplatin |
|---|---|
| VomitingGastrointestinal disorders | 2/9 |
| AnaemiaBlood and lymphatic system disorders | 1/9 |
| Abdominal pain upperGastrointestinal disorders | 1/9 |
| NauseaGastrointestinal disorders | 1/9 |
| OesophagitisGastrointestinal disorders | 1/9 |
| FatigueGeneral disorders | 1/9 |
| MalaiseGeneral disorders | 1/9 |
| DiverticulitisInfections and infestations | 1/9 |
| Lung infectionInfections and infestations | 1/9 |
| PneumoniaInfections and infestations | 1/9 |
| Event | Pemetrexed + Cisplatin |
|---|---|
| NauseaGastrointestinal disorders | 6/9 |
| AnorexiaMetabolism and nutrition disorders | 5/9 |
| Fluid retentionMetabolism and nutrition disorders | 5/9 |
| DiarrhoeaGastrointestinal disorders | 4/9 |
| StomatitisGastrointestinal disorders | 4/9 |
| FatigueGeneral disorders | 4/9 |
| HeadacheNervous system disorders | 4/9 |
| AnaemiaBlood and lymphatic system disorders | 3/9 |
| LymphopeniaBlood and lymphatic system disorders | 3/9 |
| ConstipationGastrointestinal disorders | 3/9 |
| Age, Categorical(Participants) | Pemetrexed + Cisplatin |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 4 |
| >=65 years | 5 |
| Sex: Female, Male(Participants) | Pemetrexed + Cisplatin |
|---|---|
| Female | 3 |
| Male | 6 |
| Region of Enrollment(participants) | Pemetrexed + Cisplatin |
|---|---|
| Belgium | 2 |
| Netherlands | 7 |
The record gives a start of Feb 2007, a primary completion of May 2008 and a completion of May 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Cisplatin